Physician profile
John Barbara
NPI 1487620746
$3,506.28
in general payments reported to CMS, 2019-2025
29 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $342 · 2021: $708 · 2022: $259 · 2023: $256 · 2024: $276 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $807.22 | 2021-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $515.16 | 2025 | Jornay Pm |
| Pfizer INC. | $309.39 | 2019-2025 | |
| Corium, LLC | $261.77 | 2021-2025 | Azstarys |
| Neos Therapeutics, Lp | $229.36 | 2019-2021 | |
| Tris Pharma INC | $186.52 | 2019-2025 | Onyda Xr |
| Ironshore Pharmaceuticals INC. | $147.91 | 2019-2024 | |
| Glaxosmithkline, LLC. | $141.08 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Merck Sharp & Dohme LLC | $120.74 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Genentech USA, INC. | $119.84 | 2019-2021 | |
| Adlon Therapeutics L.P. | $106.79 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.93 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $48.55 | 2024-2025 | |
| Seqirus USA INC | $41.99 | 2022-2025 | Flucelvax |
| Verrica Pharmaceuticals INC. | $41.00 | 2025 | Ycanth |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $39.91 | 2019-2023 | Immunocap |
| Cipher Pharmaceuticals US LLC | $39.71 | 2025 | Natroba, Spinosad |
| Sanofi Pasteur INC. | $39.42 | 2021-2024 | |
| Vertical Pharmaceuticals, LLC | $37.76 | 2025 | Relexxii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.52 | 2025 | Jardiance |
| Ars Pharmaceuticals Operations, INC. | $22.93 | 2025 | Neffy |
| Kyowa Kirin, INC. | $21.47 | 2025 | |
| Sobi, INC | $20.87 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $14.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2024 | Zoryve |
| Mylan Pharmaceuticals INC. | $12.78 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.57 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.